Liraglutide Impurity B [Glu]17 includes a glutamate substitution at position 17, altering local charge and helix stability. Researchers compare its folding, receptor-binding affinity, and solubility to the parent peptide. Its behavior informs degradation pathways and sequence sensitivity. Applications include impurity profiling, structural mapping, and ligand-optimization work.
CAT No: Z10-101-204
Synonyms/Alias:H-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(Pal-γ-Glu)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH; Glu(17)-Liraglutide
Liraglutide Impurity B [Glu]17 is a synthetic peptide derivative that represents a specific sequence variant within the broader class of glucagon-like peptide-1 (GLP-1) analogs. Structurally, it features a glutamic acid substitution at the seventeenth position, distinguishing it from the parent liraglutide molecule. This defined alteration makes it a valuable reference material in the context of peptide characterization and quality control, as well as a critical tool for elucidating structure-activity relationships in GLP-1 receptor agonists. Its availability supports rigorous analytical and biochemical investigations into the stability, metabolism, and functional implications of peptide modifications relevant to pharmaceutical development and peptide research.
Analytical method development: As a structurally defined impurity, Liraglutide Impurity B [Glu]17 is frequently employed in the development and validation of analytical methods such as high-performance liquid chromatography (HPLC) and mass spectrometry. Its presence allows laboratories to establish robust protocols for the detection, quantification, and differentiation of peptide impurities in complex samples. This capability is essential for ensuring the accuracy and reliability of peptide analysis, particularly in the quality assessment of synthetic GLP-1 analogs and related biopharmaceuticals.
Peptide impurity profiling: The compound serves as a critical reference standard in the qualitative and quantitative profiling of peptide impurities during manufacturing and batch release of liraglutide and its analogs. By providing a well-characterized benchmark, it enables researchers and quality control teams to monitor impurity levels, assess process consistency, and identify potential byproducts arising from peptide synthesis or degradation. Such profiling is vital for maintaining product integrity and supporting the continuous improvement of peptide production processes.
Structure-activity relationship studies: The glutamic acid substitution at position 17 in this impurity offers a unique opportunity to investigate how specific amino acid changes influence the biological activity and receptor interactions of GLP-1 analogs. By comparing functional assays and receptor binding studies with the parent compound, researchers can gain insights into the structural determinants of agonist efficacy and selectivity. This information supports rational design strategies for next-generation peptide therapeutics and enhances understanding of peptide-receptor mechanisms.
Peptide stability and degradation research: Liraglutide Impurity B [Glu]17 is instrumental in studies focused on peptide stability, degradation pathways, and the identification of potential degradation products under various storage or formulation conditions. Its use facilitates the simulation and monitoring of real-world scenarios in which peptide drugs may undergo chemical or enzymatic modifications. Such studies inform the optimization of formulation strategies, packaging, and storage parameters to minimize impurity formation and extend product shelf life.
Peptide synthesis process optimization: The availability of this impurity as a characterized reference enables process chemists and peptide manufacturers to refine synthetic routes and purification strategies. By tracking the emergence and elimination of sequence variants like [Glu]17 during peptide assembly, researchers can adjust reaction conditions, coupling protocols, and purification parameters to enhance product yield and minimize byproduct formation. This application directly supports the advancement of scalable and reproducible peptide manufacturing processes, contributing to improved efficiency and product quality.
3. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors
5. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More